Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Transplant Recipient Clear all
Completed Phase 4 Interventional Results available

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

NCT00895583
View directory record Official record
Conditions
Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Sep 30, 2026, 5:41 PM EDT
Not listed Phase 1 Interventional

Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

NCT03438773
View directory record Official record
Conditions
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
Interventions
Envarsus, Tacrolimus
Drug
Lead sponsor
California Institute of Renal Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Clazakizumab, Physiologic saline solution
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Not yet recruiting Phase 4 Interventional

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

NCT07571135
View directory record Official record
Conditions
CMV Infection, CMV, CMV Viremia, CMV Disease
Interventions
Letermovir, Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
Elisabeth Kincaide
Government
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

NCT01163799
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Alefacept (ASP0485)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

Genomics of Kidney Transplantation

NCT01714440
View directory record Official record
Conditions
KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

NCT00282230
View directory record Official record
Conditions
Kidney Transplantation
Interventions
FK778
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 30, 2026, 5:41 PM EDT
Withdrawn No phase listed Observational

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303
View directory record Official record
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

NCT03518203
View directory record Official record
Conditions
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Not applicable Interventional

Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients

NCT00235781
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Thymoglobulin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2006 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

Validation of Gene Expression Markers of Renal Allograft Functional Decline

NCT01782586
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Sirolimus Conversions in African-American Renal Transplant Recipients

NCT01005706
View directory record Official record
Conditions
Absence; Kidney
Interventions
rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Sep 30, 2026, 5:41 PM EDT
Enrolling by invitation Not applicable Interventional

Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT06336863
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
Allosure and TruGraf, Immunosuppression Taper
Diagnostic Test · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

NCT05518487
View directory record Official record
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Active, not recruiting Phase 2 Interventional

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

NCT03809533
View directory record Official record
Conditions
Kidney Transplantation, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Amit D Tevar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

NCT00034385
View directory record Official record
Conditions
Kidney Trasplant
Interventions
Valganciclovir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

NCT00266708
View directory record Official record
Conditions
Renal Transplant Osteodystrophy
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

NCT00198224
View directory record Official record
Conditions
Renal Failure
Interventions
phlebotomy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Sep 30, 2026, 5:41 PM EDT
Active, not recruiting No phase listed Observational

Blood Biomarkers in Pediatric Kidney Transplant Recipients

NCT05477082
View directory record Official record
Conditions
Rejection of Kidney Allograft
Interventions
Observational group
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

Deceased Donor Biomarkers and Recipient Outcomes

NCT01848249
View directory record Official record
Conditions
Deceased Donor Kidney Transplant, Acute Kidney Injury, Delayed Graft Function, End Stage Renal Disease, Graft Failure
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
1,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
17
States / cities
New Haven, Connecticut • Baltimore, Maryland • Waltham, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 30, 2026, 5:41 PM EDT